Breast cancer incidence in BRCA mutation carriers with ovarian cancer : A longitudal observational study
Copyright © 2021 Elsevier Inc. All rights reserved..
OBJECTIVES: We evaluated the incidence of breast cancer and overall survival in a multi-center cohort of ovarian cancer patients carrying BRCA1/2 mutations in order to assess risks and formulate optimal preventive interventions and/or surveillance.
METHODS: Medical records of 502 BRCA1/2 mutation carriers diagnosed with ovarian cancer between 2000 and 2018 at 7 medical centers in Israel and one in New York were retrospectively analyzed for breast cancer diagnosis. Data included demographics, type of BRCA mutations, surveillance methods, timing of breast cancer diagnosis, and family history of cancer.
RESULTS: The median age at diagnosis of ovarian cancer was 55.8 years (range, 23.9-90.1). A third (31.5%) had a family history of breast cancer and 17.1% of ovarian cancer. Most patients (67.3%) were Ashkenazi Jews, 72.9% were BRCA1 carriers. Breast cancer preceded ovarian cancer in 17.5% and was diagnosed after ovarian cancer in 6.2%; an additional 2.2% had a synchronous presentation. Median time to breast cancer diagnosis after ovarian cancer was 46.0 months (range, 11-168). Of those diagnosed with both breast cancer and ovarian cancer (n = 31), 83.9% and 16.1% harbored BRCA1 and BRCA2 mutations, respectively. No deaths from breast cancer were recorded. Overall survival did not differ statistically between patients with an ovarian cancer diagnosis only and those diagnosed with breast cancer after ovarian cancer.
CONCLUSION: The low incidence of breast cancer after ovarian cancer in women carrying BRCA1/2 mutations suggests that routine breast surveillance, rather than risk-reducing surgical interventions, may be sufficient in ovarian cancer survivors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Gynecologic oncology - 162(2021), 3 vom: 15. Sept., Seite 715-719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Safra, Tamar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRCA1/2 mutation |
|---|
| Anmerkungen: |
Date Completed 04.01.2022 Date Revised 04.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ygyno.2021.06.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32719393X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32719393X | ||
| 003 | DE-627 | ||
| 005 | 20231225200233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2021.06.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM32719393X | ||
| 035 | |a (NLM)34172288 | ||
| 035 | |a (PII)S0090-8258(21)00489-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Safra, Tamar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Breast cancer incidence in BRCA mutation carriers with ovarian cancer |b A longitudal observational study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2022 | ||
| 500 | |a Date Revised 04.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: We evaluated the incidence of breast cancer and overall survival in a multi-center cohort of ovarian cancer patients carrying BRCA1/2 mutations in order to assess risks and formulate optimal preventive interventions and/or surveillance | ||
| 520 | |a METHODS: Medical records of 502 BRCA1/2 mutation carriers diagnosed with ovarian cancer between 2000 and 2018 at 7 medical centers in Israel and one in New York were retrospectively analyzed for breast cancer diagnosis. Data included demographics, type of BRCA mutations, surveillance methods, timing of breast cancer diagnosis, and family history of cancer | ||
| 520 | |a RESULTS: The median age at diagnosis of ovarian cancer was 55.8 years (range, 23.9-90.1). A third (31.5%) had a family history of breast cancer and 17.1% of ovarian cancer. Most patients (67.3%) were Ashkenazi Jews, 72.9% were BRCA1 carriers. Breast cancer preceded ovarian cancer in 17.5% and was diagnosed after ovarian cancer in 6.2%; an additional 2.2% had a synchronous presentation. Median time to breast cancer diagnosis after ovarian cancer was 46.0 months (range, 11-168). Of those diagnosed with both breast cancer and ovarian cancer (n = 31), 83.9% and 16.1% harbored BRCA1 and BRCA2 mutations, respectively. No deaths from breast cancer were recorded. Overall survival did not differ statistically between patients with an ovarian cancer diagnosis only and those diagnosed with breast cancer after ovarian cancer | ||
| 520 | |a CONCLUSION: The low incidence of breast cancer after ovarian cancer in women carrying BRCA1/2 mutations suggests that routine breast surveillance, rather than risk-reducing surgical interventions, may be sufficient in ovarian cancer survivors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a BRCA1/2 mutation | |
| 650 | 4 | |a Breast Cancer | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Ovarian Cancer | |
| 650 | 4 | |a Surveillance | |
| 700 | 1 | |a Waissengrin, Barliz |e verfasserin |4 aut | |
| 700 | 1 | |a Gerber, Deanna |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein-Molho, Rinat |e verfasserin |4 aut | |
| 700 | 1 | |a Klorin, Geula |e verfasserin |4 aut | |
| 700 | 1 | |a Salman, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Josephy, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Chen-Shtoyerman, Rakefet |e verfasserin |4 aut | |
| 700 | 1 | |a Bruchim, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Frey, Melissa K |e verfasserin |4 aut | |
| 700 | 1 | |a Pothuri, Bhavana |e verfasserin |4 aut | |
| 700 | 1 | |a Muggia, Franco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologic oncology |d 1972 |g 162(2021), 3 vom: 15. Sept., Seite 715-719 |w (DE-627)NLM000614610 |x 1095-6859 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2021 |g number:3 |g day:15 |g month:09 |g pages:715-719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygyno.2021.06.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2021 |e 3 |b 15 |c 09 |h 715-719 | ||